221 related articles for article (PubMed ID: 29970615)
21. Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane.
Cho KJ; van der Hoeven D; Zhou Y; Maekawa M; Ma X; Chen W; Fairn GD; Hancock JF
Mol Cell Biol; 2016 Jan; 36(2):363-74. PubMed ID: 26572827
[TBL] [Abstract][Full Text] [Related]
22. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
23. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
24. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
26. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
28. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
29. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.
Song SP; Hennig A; Schubert K; Markwart R; Schmidt P; Prior IA; Böhmer FD; Rubio I
Biochem J; 2013 Sep; 454(2):323-32. PubMed ID: 23758196
[TBL] [Abstract][Full Text] [Related]
30. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
[TBL] [Abstract][Full Text] [Related]
31. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy.
Bartel K; Winzi M; Ulrich M; Koeberle A; Menche D; Werz O; Müller R; Guck J; Vollmar AM; von Schwarzenberg K
Oncotarget; 2017 Feb; 8(6):9476-9487. PubMed ID: 28036299
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
33. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
34. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
Elife; 2019 Nov; 8():. PubMed ID: 31674905
[TBL] [Abstract][Full Text] [Related]
35. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
36. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
37. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
38. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
Kattan WE; Hancock JF
Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
[TBL] [Abstract][Full Text] [Related]
39. Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf.
Kawabata N; Matsuda M
PLoS One; 2016; 11(12):e0167940. PubMed ID: 27936234
[TBL] [Abstract][Full Text] [Related]
40. RalA activation at nascent lamellipodia of epidermal growth factor-stimulated Cos7 cells and migrating Madin-Darby canine kidney cells.
Takaya A; Ohba Y; Kurokawa K; Matsuda M
Mol Biol Cell; 2004 Jun; 15(6):2549-57. PubMed ID: 15034142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
